## Richard J Perrin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4044554/publications.pdf

Version: 2024-02-01

55 2,464 1
papers citations h-in

65

docs citations

19 43
h-index g-index

65 3948
times ranked citing authors

254184

65 all docs

#	Article	IF	CITATIONS
1	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
2	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.8	56
3	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	7.7	19
4	Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. Journal of Proteome Research, 2022, 21, 118-131.	3.7	15
5	Quantifying regional α â€synuclein, amyloid β, and tau accumulation in lewy body dementia. Annals of Clinical and Translational Neurology, 2022, 9, 106-121.	3.7	21
6	Protracted course progressive supranuclear palsy. European Journal of Neurology, 2022, 29, 2220-2231.	<b>3.</b> 3	8
7	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
8	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
9	Flortaucipir (tau) PET in LGI1 antibody encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 491-497.	3.7	7
10	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	1.7	35
11	The Free and Cued Selective Reminding Test Predicts Braak Stage. Journal of Alzheimer's Disease, 2021, 80, 175-183.	2.6	6
12	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. Journal of Neuroimmunology, 2021, 352, 577474.	2.3	2
13	Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale–Sum of Boxes. Journal of Alzheimer's Disease, 2021, 80, 185-195.	2.6	10
14	Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. Nature, 2021, 593, 255-260.	27.8	179
15	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
16	Comparing amyloid- $\hat{l}^2$ plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
17	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature Neuroscience, 2021, 24, 1302-1312.	14.8	105
18	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	3.1	9

#	Article	IF	Citations
19	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
20	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	7.7	51
21	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. Neurolmage: Clinical, 2020, 28, 102491.	2.7	17
22	Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. Acta Neuropathologica Communications, 2020, 8, 149.	5.2	35
23	Ante―and postmortem tau in autosomal dominant and lateâ€onset Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 2475-2480.	3.7	10
24	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
25	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.8	13
26	Pituitary carcinoma: Two case reports and review of literature. World Journal of Clinical Oncology, 2020, 11, 91-102.	2.3	19
27	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research and Therapy, 2019, $11,71.$	6.2	131
28	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology, 2019, 6, 1423-1434.	3.7	22
29	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. Parkinson's Disease, 2019, 2019, 1-12.	1.1	23
30	Calvarial Langerhans cell histiocytosis in an Adult: Typical imaging findings in an atypical age group. Radiology Case Reports, 2019, 14, 1478-1482.	0.6	5
31	ICâ€Pâ€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.8	O
32	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncolmmunology, 2019, 8, e1561106.	4.6	50
33	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Molecular Neurodegeneration, 2019, 14, 18.	10.8	58
34	ICâ€Pâ€046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.8	0
35	P1â€497: CLINICAL CORRELATES OF LEWY BODY PATHOLOGY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P520.	0.8	O
36	P2â€087: EVALUATING NEUROIMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTEM HUMAN BRAIN. Alzheimer's and Dementia, 2018, 14, P701.	0.8	0

#	Article	IF	Citations
37	ICâ€Pâ€062: EVALUATING NEUROâ€IMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTHUMAN BRAIN. Alzheimer's and Dementia, 2018, 14, P57.	EM.8	0
38	Acquired mania associated with a left temporal meningioma. Bipolar Disorders, 2018, 20, 774-777.	1.9	0
39	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	3.1	42
40	Solitary Fibrous Tumor/Hemangiopericytoma Mimicking a Trigeminal Schwannoma: Case Report and Review of the Literature. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, S1-S188.	0.8	0
41	Polymer Coating Embolism: Cause of Cerebral Vasculopathy and Death following Congenital Heart Repair in Two Infants. Journal of Neuropathology and Experimental Neurology, 2017, 76, 978-980.	1.7	6
42	[ICâ€Pâ€180]: FLORTAUCIPIR TAUâ€PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDTâ€JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P134.	0.8	0
43	[S3â€"01â€"02]: NEUROPATHOLOGIC HETEROGENEITY IN FAMILIAL AND LATEâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P877.	0.8	0
44	A 66-Year-Old Woman with a Progressive, Longitudinally Extensive, Tract Specific, Myelopathy. Case Reports in Neurological Medicine, 2016, 2016, 1-9.	0.4	2
45	O3â€04â€03: Ageâ€Related Neuropathology Helps Distinguish Autosomal Dominant from Lateâ€Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P291.	0.8	0
46	A 71â€Yearâ€Old Man Presenting with Headache, Blurry Vision and Alexia without Agraphia. Brain Pathology, 2016, 26, 799-800.	4.1	1
47	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease., 2015, 11, P255-P255.		0
48	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp> Icheimer <scp>D</scp> isease <scp>N</scp> euroimaging <scp>I</scp> nitiative ( <scp>ADNI</scp> ) and the <scp>D</scp> ominantly <scp>I</scp> nherited <scp>A</scp> Izheimer <scp>N</scp> etwork ( <scp>DIAN</scp> ). Neuropathology, 2015, 35, 390-400.	1.2	68
49	O4-02-01: Age-related neuropathology helps distinguish autosomal dominant from late-onset Alzheimer disease., 2015, 11, P269-P269.		O
50	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimer's and Dementia, 2015, 11, 815-822.	0.8	46
51	Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	2.4	35
52	P1-318: NEUROPATHOLOGIC HETEROGENEITY IN ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) SUBJECTS., 2014, 10, P428-P428.		0
53	Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation. PLoS ONE, 2013, 8, e64314.	2.5	47
54	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE, 2011, 6, e16032.	2.5	152

#	Article	IF	CITATIONS
55	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, 2009, 461, 916-922.	27.8	567